Company intelligence / Profile preview

CleopatraRX Development

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Cleopatra Therapeutics is a biotechnology company focused on developing next-generation bispecific antibodies and T-cell engagers for the treatment of cancer. The company leverages its proprietary platform to design therapies that selectively target tumor cells while minimizing off-target effects and systemic toxicity. By engineering molecules with optimized binding affinities, Cleopatra aims to enhance the potency and safety profile of immunotherapy. The company's pipeline is currently in the pre-clinical stage, targeting both solid tumors and hematological malignancies.

Therapeutic areas: Oncology
Modalities: Bispecific monoclonal antibodyMonoclonal antibodyT cell engager
Industry: Biotech

Beyond the preview

Go deeper on CleopatraRX Development.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CleopatraRX Development.

Explore the full profile